In GBM, CBD inhibits the PI3K/AKT survival pathway by downregulating the phosphorylation of AKT1/2 (p-AKT) and p42/44 MAPKs without effecting the total AKT and p42/44 MAPK protein levels (Solinas et al., 2013; Scott et al., 2015). Here, AKT1 is linked to glioblastoma.